Skip to main content

Cardiol Therapeutics Inc(CRDL-T)
TSX

Today's Change
Real-Time Last Update
Day Low2.34
Day High2.58
Open:2.44
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Newsfile
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
Newsfile
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
Newsfile
Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market
Newsfile
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis
Baystreet
Stocks in play: Cardiol Therapeutics Inc.
Newsfile
Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot
Newsfile
Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
Newsfile
Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis
Newsfile
Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Newsfile
Cardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare Conference
Newsfile
Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis
Baystreet
Stocks in play: Cardiol Therapeutics Inc.
Newsfile
Cardiol Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference
Newsfile
Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market
Newsfile
Cardiol Therapeutics Reports Results of 2023 Annual General Meeting
The Globe and Mail
Cardiol Therapeutics: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (CRDL)
The Globe and Mail
Cardiol Therapeutics: Stocks trading at Less Than Cash Value on TSX (CRDL)
The Globe and Mail
Cardiol Therapeutics: Stocks trading at Less Than Cash Value on TSX (CRDL)
Newsfile
Cardiol Therapeutics Announces Year-End 2022 Update on Operations
The Globe and Mail
Cardiol Therapeutics: Stocks trading at Less Than Cash Value on TSX (CRDL)
Newsfile
Cardiol Therapeutics Announces Study Results from Collaborating Research Center Demonstrating Cardioprotective Effects of Cannabidiol in a Model of Heart Failure
The Globe and Mail
Cardiol Therapeutics: Stocks trading at Less Than Cash Value on TSX (CRDL)
Newsfile
Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx(TM) for the Treatment of Recurrent Pericarditis

Profile

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.